Cue Biopharma (CUE) Competitors $0.92 -0.08 (-8.00%) Closing price 04:00 PM EasternExtended Trading$0.93 +0.01 (+0.87%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. KRRO, PRME, NVCT, ACIU, ZYBT, BTMD, ELDN, YMAB, LFVN, and SOPHShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Korro Bio (KRRO), Prime Medicine (PRME), Nuvectis Pharma (NVCT), AC Immune (ACIU), Zhengye Biotechnology (ZYBT), biote (BTMD), Eledon Pharmaceuticals (ELDN), Y-mAbs Therapeutics (YMAB), LifeVantage (LFVN), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Korro Bio Prime Medicine Nuvectis Pharma AC Immune Zhengye Biotechnology biote Eledon Pharmaceuticals Y-mAbs Therapeutics LifeVantage SOPHiA GENETICS Cue Biopharma (NASDAQ:CUE) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Is CUE or KRRO more profitable? Korro Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Korro Bio's return on equity of -50.25% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% Korro Bio N/A -50.25%-38.48% Which has more risk & volatility, CUE or KRRO? Cue Biopharma has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Do insiders and institutionals hold more shares of CUE or KRRO? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 12.3% of Cue Biopharma shares are owned by company insiders. Comparatively, 5.4% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend CUE or KRRO? Cue Biopharma presently has a consensus target price of $4.75, suggesting a potential upside of 416.30%. Korro Bio has a consensus target price of $136.33, suggesting a potential upside of 681.73%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better earnings and valuation, CUE or KRRO? Cue Biopharma has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.53M6.11-$50.73M-$0.90-1.02Korro Bio$2.27M72.10-$81.17M-$9.39-1.86 Does the MarketBeat Community prefer CUE or KRRO? Cue Biopharma received 120 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% Korro BioOutperform Votes26100.00% Underperform VotesNo Votes Does the media favor CUE or KRRO? In the previous week, Korro Bio had 11 more articles in the media than Cue Biopharma. MarketBeat recorded 12 mentions for Korro Bio and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.89 beat Korro Bio's score of 0.32 indicating that Cue Biopharma is being referred to more favorably in the media. Company Overall Sentiment Cue Biopharma Very Positive Korro Bio Neutral SummaryKorro Bio beats Cue Biopharma on 11 of the 19 factors compared between the two stocks. Remove Ads Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.28M$6.94B$5.64B$7.82BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-1.027.1723.1318.66Price / Sales6.11221.32388.4491.28Price / CashN/A65.6738.1634.64Price / Book1.126.396.894.23Net Income-$50.73M$142.12M$3.20B$247.15M7 Day Performance-6.56%-5.05%-2.94%-2.16%1 Month Performance-25.20%-7.39%1.71%-5.65%1 Year Performance-51.32%-8.74%9.83%-0.66% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.4644 of 5 stars$0.92-8.0%$4.75+416.3%-45.7%$58.28M$9.53M-1.0260News CoveragePositive NewsKRROKorro Bio1.4919 of 5 stars$25.06+1.7%$144.00+474.6%-79.2%$234.76MN/A0.0070PRMEPrime Medicine2.851 of 5 stars$1.75-2.2%$13.13+650.0%-70.4%$229.53M$2.98M-0.85234Gap DownNVCTNuvectis Pharma2.712 of 5 stars$9.49+7.2%$15.00+58.1%+15.7%$221.99MN/A-8.188ACIUAC Immune2.48 of 5 stars$2.21-3.5%$12.00+443.0%-34.0%$218.66M$40.97M-4.80140Short Interest ↑Positive NewsZYBTZhengye BiotechnologyN/A$4.63+2.9%N/AN/A$218.38M$189.75M0.00278News CoverageBTMDbiote3.5709 of 5 stars$4.00+6.4%$8.00+100.0%-37.5%$217.35M$197.19M15.38194Gap DownHigh Trading VolumeELDNEledon Pharmaceuticals1.9292 of 5 stars$3.63-0.5%$12.50+244.4%+60.1%$216.85MN/A-1.8110Analyst RevisionNews CoveragePositive NewsYMABY-mAbs Therapeutics3.9017 of 5 stars$4.76+1.9%$19.30+305.5%-69.9%$215.24M$87.69M-8.81150LFVNLifeVantage3.8134 of 5 stars$17.04+0.1%$30.50+79.0%+142.0%$213.87M$212.15M30.43260SOPHSOPHiA GENETICS2.6906 of 5 stars$3.20-0.6%$6.80+112.5%-30.0%$213.40M$65.17M-2.94520Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Korro Bio Alternatives Prime Medicine Alternatives Nuvectis Pharma Alternatives AC Immune Alternatives Zhengye Biotechnology Alternatives biote Alternatives Eledon Pharmaceuticals Alternatives Y-mAbs Therapeutics Alternatives LifeVantage Alternatives SOPHiA GENETICS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CUE Stock Free CUE Stock Alerts